All In Biotech

Drug Trial Radar · NCT02786511

Longterm Follow-up of Subjects Treated With bb2121

Last checked: Nov 19, 2026Latest source record: Jan 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 28, 2016

Primary completion

Oct 11, 2019

Study completion Oct 11, 2019

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 1, 2016

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, non-randomized, open label, longterm safety and efficacy follow-up study for subjects who have been treated with bb2121 in the Phase 1 clinical parent study, that evaluated the safety and efficacy of bb2121 in subjects with relapsed or refractory B cell maturation antigen (BCMA)-expressing multiple myeloma. bb2121 is defined as autologous T lymphocytes (T cells) transduced ex vivo with anti-BCMA02 CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA suspended in cryopreservative solution. bb2121 is administered in subjects 1 time (or retreated if retreatment criteria are met) in parent clinical study. No investigational treatment will be administered in this study. After completing the parent study, eligible subjects will be followed for up to 15 years after their last bb2121 infusion in the parent study.

Conditions

  • Multiple Myeloma

Interventions

  • Safety and efficacy assessmentsDrug

    Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 15 years post-drug product infusion
  2. Monitoring for all Adverse Events, including Serious Adverse Events, related to the drug productTime frame: 15 years post-drug product infusion
  3. Monitoring for all Serious Adverse Events including any new malignancy or new diagnosis of a neurologic, rheumatologic, or hematologic disorder that is clinically significantTime frame: 5 years post-drug product infusion
  4. Monitoring for Multiple Myeloma-specific response according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple MyelomaTime frame: 5-15 years post-drug product infusion
  5. Progression Free SurvivalTime frame: 5-15 years post-drug product infusion
  6. Monitoring for Vector Copy Number (VCN)Time frame: 5-15 years post-drug product infusion

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Cancer Center

    Palo Alto, California

  • National Cancer Institute

    Bethesda, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mount Sinai Medical Center

    New York, New York

  • Sarah Cannon Research Institute

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.